Search

Guardant Health Inc

Suletud

SektorTervishoid

183.78 3.06

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

172.37

Max

178.52

Põhinäitajad

By Trading Economics

Sissetulek

-8.1M

-120M

Müük

33M

335M

Aktsiakasum

-0.89

Kasumimarginaal

-35.866

Töötajad

2,490

EBITDA

-8.1M

-109M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+17.72% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

5. nov 2026

Turustatistika

By TradingEconomics

Turukapital

4B

23B

Eelmine avamishind

180.72

Eelmine sulgemishind

183.78

Guardant Health Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. okt 2026, 20:07 UTC

News

BTIG analyst Mark Massaro raised the price target on Guardant Health to $210 from $195, maintaining a Buy rating due to strong growth prospects.

26. okt 2026, 20:07 UTC

Guardant Health Inc is advancing today, reflecting a notable gain since Friday's close, with the stock remaining above its 20-day moving average.

22. okt 2026, 20:07 UTC

Guardant Health Inc shares are declining, reaching a low point around midday and closing significantly below Wednesday's close, remaining below its 20-day moving average.

21. okt 2026, 19:56 UTC

Guardant Health Inc shares are advancing, having earlier reached a peak before retracing, currently trading below the 20-day moving average.

20. okt 2026, 20:08 UTC

News
Social Media

Guardant Health Inc will present 25 abstracts at the ESMO Congress 2026, focusing on advancements in circulating tumor DNA monitoring across various cancer types.

19. okt 2026, 20:07 UTC

News

Guardant Health Inc shares are lower amid legal pressures from a U.S. patent ruling affecting its Duplex Sequencing technology and recent test data release.

16. okt 2026, 20:02 UTC

Social Media

Guardant Health Inc shares are declining following a recent loss in a DNA sequencing patent challenge against TwinStrand, marking its second setback in ongoing disputes.

15. okt 2026, 19:41 UTC

News

Guardant Health presents new data at the American College of Gastroenterology meeting, highlighting the effectiveness of its blood-based testing for colorectal cancer screening.

14. okt 2026, 19:31 UTC

Guardant Health Inc is rising amid a notable increase in the Health Care Services sector, with unusually high market volume today.

12. okt 2026, 20:07 UTC

Guardant Health Inc shares are declining, continuing a downward trend from Friday's close, reaching a session low before stabilizing near the lower end of its one-month range.

8. okt 2026, 20:07 UTC

Guardant Health Inc shares are declining amid a broader market downturn, reflecting ongoing pressures from rising mortgage rates and credit condition concerns.

7. okt 2026, 20:07 UTC

News

Shares of Guardant Health Inc declined despite Barclays raising the price target to $220.00 from $200.00, finishing significantly below their 20-day moving average.

6. okt 2026, 23:05 UTC

Guardant Health Inc is trading modestly lower in after-hours action, continuing a downward trend since Tuesday's close and remaining below its 20-day moving average.

5. okt 2026, 23:45 UTC

Guardant Health Inc's shares advanced in after-market hours, recovering from earlier declines and remaining significantly above the 20-day moving average.

2. okt 2026, 20:07 UTC

Guardant Health Inc is advancing amid a broadly higher market, supported by declining U.S. Treasury yields and recent labor statistics indicating potential economic challenges.

1. okt 2026, 19:15 UTC

Guardant Health Inc shares fell sharply after reaching an early high, hitting a low before 2 PM, though still above its 20-day moving average.

30. sept 2026, 20:07 UTC

Guardant Health Inc is advancing during Wednesday's session, regaining ground after pulling back earlier, and remains above its 20-day moving average.

28. sept 2026, 19:16 UTC

Social Media

Guardant Health's Shield blood test is now covered for about 70 million Americans, yet shares are declining amid fluctuating trading activity.

24. sept 2026, 19:35 UTC

Social Media

Shares of Guardant Health Inc are trading lower despite social media attention on its new blood test for detecting common cancers, emphasizing early detection.

22. sept 2026, 19:55 UTC

Guardant Health Inc shares are higher, reflecting positive trading activity and reaching a peak return earlier in the session, while remaining above its 20-day moving average.

21. sept 2026, 23:06 UTC

Guardant Health Inc saw modest gains in after-market trading, remaining above its 20-day moving average and near the upper end of its one-month range.

18. sept 2026, 22:11 UTC

Guardant Health Inc is gaining in after-market trading, reaching a peak return and remaining significantly above its 20-day moving average.

17. sept 2026, 19:56 UTC

Guardant Health Inc is trading sharply higher, reaching its highest cumulative return since Wednesday and well above its 20-day moving average.

16. sept 2026, 19:16 UTC

Guardant Health Inc is trading roughly flat, maintaining a slight range and positioned near the upper end of its one-month trading range.

15. sept 2026, 23:31 UTC

Guardant Health Inc shares are lower in after-market hours, continuing a decline since Tuesday's close, with no specific news identified to explain the movement.

14. sept 2026, 20:02 UTC

Guardant Health Inc shares are higher today, driven by unusually high trading volume, despite broader market concerns over rising crude oil prices and inflation.

11. sept 2026, 20:08 UTC

Guardant Health Inc shares are lower today, continuing a trend since Thursday's close. The stock is trading below its 20-day moving average.

10. sept 2026, 20:07 UTC

Guardant Health Inc shares are lower today, reflecting broader market declines. The stock peaked earlier but has since reached a session low.

8. sept 2026, 20:08 UTC

News
Event

Guardant Health recognized by Business Insider for innovation in biotechnology. Shares are lower today, pulling back from earlier session highs.

4. sept 2026, 20:02 UTC

Guardant Health Inc shares are lower today, extending a decline over three sessions. High trading volume accompanies the move amid unchanged unemployment data.

Võrdlus sarnastega

Hinnamuutus

Guardant Health Inc Prognoos

Hinnasiht

By TipRanks

17.72% tõus

12 kuu keskmine prognoos

Keskmine 203.944 USD  17.72%

Kõrge 225 USD

Madal 180 USD

Põhineb 20 Wall Streeti analüütiku instrumendi Guardant Health Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

20 ratings

20

Osta

0

Hoia

0

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat